Inify Laboratories and Karolinska Institutet's ProMort Team Partner to Transform Prostate Cancer Diagnostics with AI

UK Government and Oxford Nanopore Forge Partnership to Advance Genomics in the NHS, Enhancing Patient Care and Biosecurity

HuidaGene Therapeutics Gains FDA Clearance for First CRISPR/Cas13 RNA-Editing Therapy HG202 to Treat Macular Degeneration

Complete Genomics Unveils New Sequencing Innovations and Expanded DNBSEQ-T7 Applications at ASHG 2024

QIAGEN’s QIAstat-Dx Meningitis/Encephalitis Panel Gains FDA Clearance, Accelerating CNS Infection Diagnosis

Tempus AI to Acquire Ambry Genetics for $600 Million, Expanding Genetic Testing Capabilities

Aiforia and Paige form strategic partnership to advance AI integration in pathology laboratories

CytoDyn Receives FDA Clearance to Begin Phase II Trial of Leronlimab for Colorectal Cancer

MGM Medical College in Indore Pioneers CAR T Cell Therapy for Blood Cancer Treatment in India’s Public Healthcare System

AbbVie and EvolveImmune Therapeutics Partner in New Collaboration and Licensing Agreement to Advance Next-Generation Cancer Biotherapeutics

Cardiff Oncology Publishes Phase 2 Trial Data on Second-Line Treatment for KRAS-Mutant mCRC in *Journal of Clinical Oncology*

Advanced Genomics APAC and Compass Bioinformatics Forge Strategic Alliance to Enhance Rare Disease and Cancer Diagnostics in APAC Region

Telo Genomics Expands Mayo Clinic Collaboration to Advance Multiple Myeloma Prognostic Testing

Daiichi Sankyo and AstraZeneca Launch Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations in Advanced Non-Small Cell Lung Cancer

FDA Approves Novartis Scemblix® for Newly Diagnosed CML, Showcasing Superior Efficacy and Improved Safety Profile

Home
/
update
/
details

UK Government and Oxford Nanopore Forge Partnership to Advance Genomics in the NHS, Enhancing Patient Care and Biosecurity

NextEdge Admin

06 Nov 2024

3 min 58 sec

Oxford Nanopore has announced a strategic partnership with the UK Government to integrate advanced genomics technology across the NHS, supported by Genomics England, UK Biobank, and NHS England. This partnership aims to propel the NHS towards being "fit for the future," with genomics-based research improving patient care while driving innovation in the UK’s life sciences sector.

The collaboration will harness Oxford Nanopore’s rapid, scalable sequencing technology, known for its ability to produce rich genomic insights. The partnership’s focus includes cancer, rare genetic diseases, and infectious disease management. For example, in cancer care, genomic data can guide personalized treatment, while for rare genetic conditions, detailed DNA analysis can enable more accurate diagnoses and tailored therapies. Broader applications like newborn genetic screening and pharmacogenomics—where genetic profiles influence medication choices—are also on the horizon, with potential to further personalize medicine in the UK.

A critical component of this collaboration is the establishment of a first-of-its-kind, pathogen-agnostic biosurveillance system across 30 NHS hospitals. Developed in partnership with NHS England and piloted at Guy’s and St Thomas’ NHS Foundation Trust, this system will significantly expand the NHS Respiratory Metagenomics programme. By providing real-time pathogen detection and supporting the UK Health Security Agency, the system is designed as an early warning framework to identify and respond to emerging biological threats, enhancing national biosecurity in line with the UK Biological Security Strategy. This initiative will launch in 2025 and aims for a groundbreaking six-hour timeline for identifying and characterizing respiratory diseases, including antimicrobial resistance, enabling faster critical care interventions and reducing hospital strain.

The NHS will also benefit from Oxford Nanopore’s technology for faster, more precise diagnostics in cancer and rare disease, aiming to translate laboratory breakthroughs into routine patient care. This alignment with the Government’s 10-Year Health Plan emphasizes moving NHS diagnostics from analogue to digital, providing patients with earlier, more accurate diagnoses and personalized treatment paths.

Beyond healthcare improvements, the partnership is expected to stimulate the UK economy by strengthening its life sciences sector and creating high-value jobs. As a global leader in genomic innovation, the UK will attract further investment and talent. NHS staff and researchers will have access to training, ensuring a skilled workforce ready to leverage genomics for enhanced patient care and economic growth.

This collaboration underscores the UK’s commitment to leading in genomics-based healthcare, with benefits expected for both patients and the broader life sciences community.